Cartesian Therapeutics (RNAC) Enters $130M Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Oppenheimer Downgrades Cartesian Therapeutics (RNAC) to Perform
July 2, 2024 11:27 AM EDTOppenheimer analyst Matthew Biegler downgraded Cartesian Therapeutics (NASDAQ: RNAC) from Outperform to Perform.
The analyst comments "Weve been bullish on this nameand while the topline results looked excellent at first glance, we just cant get over the ITT versus per protocol... More



